AstraZeneca Results Presentation Deck

Late-stage pipeline events in the 2021-2022 timeframe Busy news flow continues; Phase III readouts increase into 2021 Regulatory decision 34 Regulatory submission and/or acceptance Key Phase III data readouts Status as of 11 February 2021. H1 2021 Tagrisso-adjuvant NSCLC (EGFRM) (CN) Lynparza - breast cancer (BRCAm) (CN) Koselugo - neurofibromatosis type 1 (NF1) (EU) Farxiga - CKD (US) Brilique/Brilinta - CAD/T2D CVOT (EU, JP, CN) Brilique - stroke (THALES) (EU) roxadustat - anaemia in CKD (US) Symbicort - mild asthma (EU) Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2) Calquence - CLL (R/R) (ELEVATE R/R) Fasenra - nasal polyps tezepelumab - severe asthma COVID-19 Vaccine AstraZeneca - SARS-CoV-2 (US, JP) AZD7442 - SARS-CoV-2 Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2) Imfinzi +/-treme - NSCLC (1L) (POSEIDON) (OS) Lynparza - adjuvant breast cancer COVID-19 Vaccine AstraZeneca - SARS-CoV-2 AZD7442 - SARS-CoV-2 H2 2021 Tagrisso-adjuvant NSCLC (EGFRM) (EU) Lynparza - prostate cancer (2L) (CN) Forxiga - CKD (EU, JP, CN) Brilinta - stroke (THALES) (CN) anifrolumab - lupus (SLE) (US, EU, JP) Imfinzi - NSCLC (1L) (PEARL) Imfinzi +/- treme - NSCLC (1L) (POSEIDON) Imfinzi +/-treme - liver cancer (1L) Lynparza - adjuvant breast cancer Lynparza - prostate cancer (1L, castration-resistant) Enhertu - breast cancer (2L, HER2+) Imfinzi - NSCLC (1L) (PEARL) Imfinzi +/-treme - liver cancer (1L) Lynparza - prostate cancer (1L, castration-resistant) Enhertu - breast cancer (3L, HER2+) (Phase III) Enhertu - breast cancer (2L, HER2+) Enhertu - breast cancer (HER2 low) Farxiga - HF (HFpEF) PT027- asthma 2022 Imfinzi - ES-SCLC (CN) Imfinzi - limited-stage SCLC Imfinzi - liver cancer (locoregional) Imfinzi - biliary tract cancer Lynparza - ovarian cancer (3L, BRCAM) Enhertu - breast cancer (3L, HER2+) (Phase III) Enhertu - breast cancer (HER2 low) Calquence - CLL (CN) Koselugo - NF1 (JP, CN) Farxiga - HF (HFpEF) roxadustat - anaemia in myelodysplastic syndrome PT027-asthma Imfinzi - limited-stage SCLC Imfinzi - liver cancer (locoregional) Imfinzi - biliary tract cancer roxadustat - anaemia in myelodysplastic syndrome nirsevimab - respiratory syncytial virus B

View entire presentation